Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes

Lima, Marcelo de; Kwon, Byungjoon; Ansari, Israrul H.; Pattnaik, Asit K.; Flores, Eduardo F.; Osorio, Fernando A.

doi:10.1016/j.vaccine.2008.04.078

Cited by 37 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine, when administered intramuscularly, however, failed to confer respiratory and viremia protection [13] . There is also an effort to produce a PRRS vaccine that can differentiate infected from vaccinated animals for PRRS eradication [65] . This is accomplished by a deletion of 15-mer of non-structural protein 2 (nsp2) epitope of PRRSV.…”

Section: Current Efforts On Prrs Vaccine Developmentmentioning

confidence: 99%

Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects

Charerntantanakul¹

2012

WJV

152

131

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome virus (PRRSV) infection is the leading cause of economic casualty in swine industry worldwide. The virus can cause reproductive failure, respiratory disease, and growth retardation in the pigs. This review deals with current status of commercial PRRS vaccines presently used to control PRRS. The review focuses on the immunogenicity, protective efficacy and safety aspects of the vaccines. Commercial PRRS modified-live virus (MLV) vaccine elicits delayed humoral and cell-mediated immune responses following vaccination. The vaccine confers late but effective protection against genetically homologous PRRSV, and partial protection against genetically heterologous virus. The MLV vaccine is of concern for its safety as the vaccine virus can revert to virulence and cause diseases. PRRS killed virus (KV) vaccine, on the other hand, is safe but confers limited protection against either homologous or heterologous virus. The KV vaccine yet helps reduce disease severity when administered to the PRRSV-infected pigs. Although efforts have been made to improve the immunogenicity, efficacy and safety of PRRS vaccines, a better vaccine is still needed in order to protect against PRRSV.

show abstract

Section: Current Efforts On Prrs Vaccine Developmentmentioning

confidence: 99%

Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects

Charerntantanakul¹

2012

WJV

152

131

View full text Add to dashboard Cite

show abstract

“…Herpesvirus negative marker vaccines were first developed in 1980, and their use has contributed to disease control and eradication in some countries [11,37,38]. Following the successes of these vaccines, negative marker vaccines of some animal diseases have been developed by identifying and selecting non-essential genes [35,39-42], and some of them have successfully been used to control disease outbreaks [9,10]. …”

Section: Discussionmentioning

confidence: 99%

Evaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine

Bai

et al. 2014

Vet Res

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease of cloven-hoofed animals in the world. The disease can be effectively controlled by vaccination of susceptible animals with the conventional inactivated vaccine. However, one major concern of the inactivated FMD virus (FMDV) vaccine is that it does not allow serological discrimination between infected and vaccinated animals, and therefore interferes with serologic surveillance and the epidemiology of disease. A marker vaccine has proven to be of great value in disease eradication and control programs. In this study, we constructed a marker FMDV containing a deletion of residues 93 to 143 in the nonstructural protein 3A using a recently developed FMDV infectious cDNA clone. The marker virus, r-HN/3A93–143, had similar growth kinetics as the wild type virus in culture cell and caused a symptomatic infection in pigs. Pigs immunized with chemically inactivated marker vaccine were fully protected from the wild type virus challenge, and the potency of this marker vaccine was 10 PD50 (50% pig protective dose) per dose, indicating it could be an efficacious vaccine against FMDV. In addition, we developed a blocking ELISA targeted to the deleted epitope that could clearly differentiate animals infected with the marker virus from those infected with the wild type virus. These results indicate that a marker FMDV vaccine can be potentially developed by deleting an immunodominant epitope in NSP 3A.

show abstract

“…Thus far, efforts to develop a DIVA vaccine for PRRSV have been focused on deleting different immunogenic fragments of the viral nsp2 because this protein can tolerate large deletions [41–43]. However, the biggest shortcoming of the nsp2-mutant viruses, in the context of a DIVA vaccine, is that the differential peptide-based ELISA used in conjunction with the DIVA vaccine has very limited diagnostic sensitivity [42], mainly due to the substantial genetic variation of the nsp2 [44,45]. …”

Section: Discussionmentioning

confidence: 99%

Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

Kwon

Lima

et al. 2013

Vaccine

Self Cite

View full text Add to dashboard Cite

DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful for control and eradication of infectious diseases in livestock. We describe here the characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential target for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues 161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the introduction of a single amino acid mutation which does not adversely affect the viral replication. All together, our results provide an important starting point for the development of a live-attenuated DIVA vaccine against type-II PRRSV.

show abstract

Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes

Cited by 37 publications

References 30 publications

Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects

Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects

Evaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine

Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

Contact Info

Product

Resources

About